Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer | Synapse
September 13, 2024
Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Prognostic value of on-treatment ctDNA TF detection and 90% PSA reduction